Physician profile
Jose Ortiz
NPI 1487667127
$18,289.56
in general payments reported to CMS, 2019-2025
50 companies · $2,653 in 2025
The $2,653 reported for 2025 was more than what 81% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,588 · 2020: $1,853 · 2021: $3,141 · 2022: $2,533 · 2023: $2,484 · 2024: $3,038 · 2025: $2,653.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,136 · Education: $39.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,135.77 |
| Education | $39.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,148.44 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $1,529.90 | 2019-2025 | Evenity, Prolia, Repatha |
| Dexcom, INC. | $1,463.04 | 2019-2025 | Dexcom G6 Transmitter |
| Tandem Diabetes Care, INC. | $1,355.79 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,182.60 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $1,153.86 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $791.09 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $786.34 | 2019-2023 | Farxiga, Lokelma |
| Sanofi-Aventis U.S. LLC | $628.66 | 2019-2025 | |
| Abbott Laboratories | $555.78 | 2019-2025 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $550.94 | 2022-2025 | |
| Xeris Pharmaceuticals, INC. | $519.19 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Amarin Pharma, INC. | $515.78 | 2019-2021 | |
| Corcept Therapeutics | $480.09 | 2019-2025 | Korlym |
| Medtronic, INC. | $448.64 | 2021-2025 | Minimed 780g, Inpen Smart Insulin Delivery System, Endurant Iis |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Ortiz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.